Roche's PD-L1 Contender Makes Strides In NSCLC Rival Chase
This article was originally published in Scrip
Executive Summary
Roche AG/Genentech is strengthening its hand in immuno-oncology with new data for its anti-PD-L1 product atezolizumab showing promise in a large Phase II trial in non-small cell lung cancer. It needs the positive results in order to compete with the leading PD-1 players, Bristol-Myers Squibb's Opdivo (nivolumab), which is already approved in NSCLC, and Merck & Co's Keytruda (pembrolizumab), which is awaiting approval for this indication (both products are already on the market for melanoma).